A Scoping Review of Personalized, Interactive, Web-Based Clinical Decision Tools Available for Breast Cancer Prevention and Screening in the United States.

IF 1.7 Q3 HEALTH CARE SCIENCES & SERVICES MDM Policy and Practice Pub Date : 2024-03-17 eCollection Date: 2024-01-01 DOI:10.1177/23814683241236511
Dalya Kamil, Kaitlyn M Wojcik, Laney Smith, Julia Zhang, Oliver W A Wilson, Gisela Butera, Jinani Jayasekera
{"title":"A Scoping Review of Personalized, Interactive, Web-Based Clinical Decision Tools Available for Breast Cancer Prevention and Screening in the United States.","authors":"Dalya Kamil, Kaitlyn M Wojcik, Laney Smith, Julia Zhang, Oliver W A Wilson, Gisela Butera, Jinani Jayasekera","doi":"10.1177/23814683241236511","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction.</b> Personalized web-based clinical decision tools for breast cancer prevention and screening could address knowledge gaps, enhance patient autonomy in shared decision-making, and promote equitable care. The purpose of this review was to present evidence on the availability, usability, feasibility, acceptability, quality, and uptake of breast cancer prevention and screening tools to support their integration into clinical care. <b>Methods.</b> We used the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews Checklist to conduct this review. We searched 6 databases to identify literature on the development, validation, usability, feasibility, acceptability testing, and uptake of the tools into practice settings. Quality assessment for each tool was conducted using the International Patient Decision Aid Standard instrument, with quality scores ranging from 0 to 63 (lowest-highest). <b>Results.</b> We identified 10 tools for breast cancer prevention and 9 tools for screening. The tools included individual (e.g., age), clinical (e.g., genomic risk factors), and health behavior (e.g., alcohol use) characteristics. Fourteen tools included race/ethnicity, but no tool incorporated contextual factors (e.g., insurance, access) associated with breast cancer. All tools were internally or externally validated. Six tools had undergone usability testing in samples including White (median, 71%; range, 9%-96%), insured (99%; 97%-100%) women, with college education or higher (60%; 27%-100%). All of the tools were developed and tested in academic settings. Seven (37%) tools showed potential evidence of uptake in clinical practice. The tools had an average quality assessment score of 21 (range, 9-39). <b>Conclusions.</b> There is limited evidence on testing and uptake of breast cancer prevention and screening tools in diverse clinical settings. The development, testing, and integration of tools in academic and nonacademic settings could potentially improve uptake and equitable access to these tools.</p><p><strong>Highlights: </strong>There were 19 personalized, interactive, Web-based decision tools for breast cancer prevention and screening.Breast cancer outcomes were personalized based on individual clinical characteristics (e.g., age, medical history), genomic risk factors (e.g., BRCA1/2), race and ethnicity, and health behaviors (e.g., smoking). The tools did not include contextual factors (e.g., insurance status, access to screening facilities) that could potentially contribute to breast cancer outcomes.Validation, usability, acceptability, and feasibility testing were conducted mostly among White and/or insured patients with some college education (or higher) in academic settings. There was limited evidence on testing and uptake of the tools in nonacademic clinical settings.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"9 1","pages":"23814683241236511"},"PeriodicalIF":1.7000,"publicationDate":"2024-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946080/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MDM Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23814683241236511","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. Personalized web-based clinical decision tools for breast cancer prevention and screening could address knowledge gaps, enhance patient autonomy in shared decision-making, and promote equitable care. The purpose of this review was to present evidence on the availability, usability, feasibility, acceptability, quality, and uptake of breast cancer prevention and screening tools to support their integration into clinical care. Methods. We used the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews Checklist to conduct this review. We searched 6 databases to identify literature on the development, validation, usability, feasibility, acceptability testing, and uptake of the tools into practice settings. Quality assessment for each tool was conducted using the International Patient Decision Aid Standard instrument, with quality scores ranging from 0 to 63 (lowest-highest). Results. We identified 10 tools for breast cancer prevention and 9 tools for screening. The tools included individual (e.g., age), clinical (e.g., genomic risk factors), and health behavior (e.g., alcohol use) characteristics. Fourteen tools included race/ethnicity, but no tool incorporated contextual factors (e.g., insurance, access) associated with breast cancer. All tools were internally or externally validated. Six tools had undergone usability testing in samples including White (median, 71%; range, 9%-96%), insured (99%; 97%-100%) women, with college education or higher (60%; 27%-100%). All of the tools were developed and tested in academic settings. Seven (37%) tools showed potential evidence of uptake in clinical practice. The tools had an average quality assessment score of 21 (range, 9-39). Conclusions. There is limited evidence on testing and uptake of breast cancer prevention and screening tools in diverse clinical settings. The development, testing, and integration of tools in academic and nonacademic settings could potentially improve uptake and equitable access to these tools.

Highlights: There were 19 personalized, interactive, Web-based decision tools for breast cancer prevention and screening.Breast cancer outcomes were personalized based on individual clinical characteristics (e.g., age, medical history), genomic risk factors (e.g., BRCA1/2), race and ethnicity, and health behaviors (e.g., smoking). The tools did not include contextual factors (e.g., insurance status, access to screening facilities) that could potentially contribute to breast cancer outcomes.Validation, usability, acceptability, and feasibility testing were conducted mostly among White and/or insured patients with some college education (or higher) in academic settings. There was limited evidence on testing and uptake of the tools in nonacademic clinical settings.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对美国乳腺癌预防和筛查中可用的个性化、交互式、基于网络的临床决策工具的范围审查。
导言。针对乳腺癌预防和筛查的个性化网络临床决策工具可以弥补知识差距,提高患者在共同决策中的自主权,并促进公平护理。本综述旨在提供有关乳腺癌预防和筛查工具的可用性、可用性、可行性、可接受性、质量和使用率的证据,以支持将这些工具纳入临床护理。方法。我们使用《系统综述和元分析首选报告项目扩展范围综述核对表》进行了此次综述。我们检索了 6 个数据库,以确定有关工具的开发、验证、可用性、可行性、可接受性测试以及在实践中的应用情况的文献。我们使用国际患者决策辅助标准工具对每种工具进行了质量评估,质量评分范围为 0 至 63 分(最低-最高)。结果。我们确定了 10 种乳腺癌预防工具和 9 种筛查工具。这些工具包括个人(如年龄)、临床(如基因组风险因素)和健康行为(如饮酒)特征。有 14 种工具包括种族/民族,但没有一种工具包括与乳腺癌相关的背景因素(如保险、就医途径)。所有工具均经过内部或外部验证。六款工具在样本中进行了可用性测试,其中包括白人(中位数,71%;范围,9%-96%)、有保险(99%;97%-100%)、大学或以上学历(60%;27%-100%)的女性。所有工具都是在学术环境中开发和测试的。有七种(37%)工具显示出在临床实践中被采用的潜在证据。这些工具的平均质量评估分数为 21 分(范围为 9-39)。结论。关于乳腺癌预防和筛查工具在不同临床环境中的测试和使用情况的证据有限。在学术和非学术环境中开发、测试和整合工具可能会提高这些工具的使用率和公平性:根据个人临床特征(如年龄、病史)、基因组风险因素(如 BRCA1/2)、种族和民族以及健康行为(如吸烟),对乳腺癌结果进行了个性化处理。这些工具并不包括可能对乳腺癌结果产生潜在影响的环境因素(如保险状况、筛查设施的可及性)。验证、可用性、可接受性和可行性测试主要是在学术环境中对受过一定大学教育(或更高)的白人和/或投保患者进行的。有关在非学术临床环境中测试和使用这些工具的证据有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
MDM Policy and Practice
MDM Policy and Practice Medicine-Health Policy
CiteScore
2.50
自引率
0.00%
发文量
28
审稿时长
15 weeks
期刊最新文献
Shared Decision Making and Its Association with Antiviral Therapy Adherence in Patients with Chronic Hepatitis B: Single-Center Cross-Sectional Analysis. Understanding Factors Influencing Decision Making during Assessment of Potential Organ Donors: A Qualitative Study of Clinicians Assessing the Medical Suitability of Potential Donors. Treatment Preferences among Patients with Hormone-Sensitive Prostate Cancer in France, Spain, China, South Korea, and Japan: A Discrete-Choice Experiment. Barriers and Facilitators for Shared Decision Making in Breast Reconstruction among Stakeholders in the Chinese Context: A Qualitative Study. Integrating Decision Science and Implementation Science to Inform Policy Decision Making.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1